摘要
目的探讨重组人血管内皮抑制素联合奈达铂治疗非小细胞肺癌合并恶性胸腔积液的耐药性。方法选取92例非小细胞肺癌合并恶性胸腔积液患者作为研究对象,分为对照组和观察组,各46例。留取每位患者无变性、无坏死的新鲜非小细胞肺癌组织。对照组予奈达铂处理,观察组予奈达铂+重组人血管内皮抑制素处理,比较两组患者治疗前后的P糖蛋白(P-gp)表达情况。结果治疗前两组患者P-gp阳性表达率比较,差异无统计学意义。治疗后观察组患者P-gp阳性率下降为39.47%,对照组阳性率上升为89.23%,两组比较差异有统计学意义(χ^2=13.70,P﹤0.01)。结论联合应用重组人血管内皮抑制素和奈达铂可以降低非小细胞肺癌合并恶性胸腔积液患者P-gp阳性表达率,可以一定程度提高治疗效果,为进一步研究晚期肺癌的治疗方法提供参考。
Objective To investigate the drug resistance of recombinant human endostatin combined with nedaplatin in the treatment of patients with non-small cell lung cancer(NSCLC)and malignant pleural effusion(MPE).Method A total of 92 patients with NSCLC and MPE were selected and divided into control group and experimental group with 46 cases in either group.The fresh NSCLC tissues without degeneration or necrosis were collected from each patient.The control group was treated with nedaplatin,and the experimental group was treated with nedaplatin combined with recombinant human endostatin.The expression of P-glycoprotein(P-gp)before and after treatment was compared between the two groups.Result Before the treatment,there was no significant difference between the two groups in positive expression rate.After the treatment,the positive rate of P-gp decreased to 39.47%in the experimental group while the index increased to 89.23%in the control group.The difference between the two groups was statistically significant(χ^2=13.70,P<0.01).Conclusion The combination of recombinant human endostatin and nedaplatin can reduce the positive expression rate of P-gp in patients with NSCLC and MPE,and improve the effect to a certain extent.This study provides a reference for further study on the treatment of advanced lung cancer.
作者
程少先
谭诗云
CHENG Shaoxian;TAN Shiyun(Department of Thoracic Surgery,Jingshan Union Hospital of Huazhong University of Science and Technology,Jingshan 431800,Hubei,China;Department of Neurology,Jingshan Union Hospital of Huazhong University of Science and Technology,Jingshan 431800,Hubei,China)
出处
《癌症进展》
2020年第18期1870-1872,1906,共4页
Oncology Progress
基金
湖北省卫生健康科研项目(WJ2019F116)。
